Whole exome sequencing of 69 essential thrombocythemia patients
收藏NIAID Data Ecosystem2026-03-13 收录
官方服务：
资源简介：
Phase IV trial of anagrelide for high risk ET
应用场景：
创建时间：
2022-06-27
相关数据集
Summary results for Xeloda noninferiority trial from Rothmann’s, Wang’s, and Ratio tests, and GPV-based method.
Summary results for Xeloda noninferiority trial from Rothmann’s, Wang’s, and Ratio tests, and GPV-based method.
figshare.com2023-06-03 更新30
Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia
The identification of gene mutation and structural genomic aberrations that are critically involved in CLL pathogenesis is still evolving. One may postulate that genomic driver lesions with effects o
NIAID Data Ecosystem10
Table 1_Characteristics of pediatric interventional drug trials registered between 2015 and 2024 on ClinicalTrials.gov.xlsx
AimThis study comprehensively analyzed the characteristics and development trends of pediatric interventional drug clinical trials registered between 2015 and 2024, with a focus on pharmaceutical char
NIAID Data Ecosystem00
A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors
The PI3K/Akt/mTOR signaling pathway is aberrantly activated in various pediatric tumors. We conducted a phase I study of the Akt inhibitor perifosine in patients with recurrent/refractory pediatric CN
NIAID Data Ecosystem30
Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia. Clinical impact of clonal architecture in CLL
Genome studies of chronic lymphocytic leukemia (CLL) have revealed the remarkable subclonal heterogeneity of the tumors, but the clinical implications of this phenomenon are not well known. We assesse
NIAID Data Ecosystem10
